1. Home
  2. CALX vs NUVB Comparison

CALX vs NUVB Comparison

Compare CALX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calix Inc

CALX

Calix Inc

HOLD

Current Price

$50.52

Market Cap

3.4B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.66

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALX
NUVB
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.9B
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CALX
NUVB
Price
$50.52
$4.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
9
Target Price
$74.75
$11.22
AVG Volume (30 Days)
1.1M
4.8M
Earning Date
04-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
157.78
N/A
EPS
0.26
N/A
Revenue
$510,367,000.00
N/A
Revenue This Year
$16.40
$182.76
Revenue Next Year
$13.75
$91.83
P/E Ratio
$200.15
N/A
Revenue Growth
11.24
N/A
52 Week Low
$28.61
$1.57
52 Week High
$71.22
$9.75

Technical Indicators

Market Signals
Indicator
CALX
NUVB
Relative Strength Index (RSI) 43.04 33.85
Support Level $45.38 $3.92
Resistance Level $56.17 $5.73
Average True Range (ATR) 2.45 0.35
MACD -0.13 -0.07
Stochastic Oscillator 1.53 25.27

Price Performance

Historical Comparison
CALX
NUVB

About CALX Calix Inc

Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: